Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Duke University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01738646CT.gov Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients | — | Completed | — | — | — |
NCT01378481CT.gov High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | — | Terminated | — | — | — |
NCT01110876CT.gov Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | — | Terminated | — | — | — |
NCT00946673CT.gov Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00268385CT.gov Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vorinostat (this asset) | Duke University | P2 | B · 60 |
| Irinotecan | University of California, Davis | P2 | BBB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Sorafenib | Virginia Commonwealth University | P2 | BB |
| Cyclophosphamide | Essen Biotech | P2 | BB |
| Dianhydrogalactitol | Kintara Therapeutics, Inc. | P2 | BB |
| Carboplatin | John L. Villano, MD, PhD | P3 | B |
| Capecitabine | Northwell Health | P2 | B |
| Indoximod | NewLink Genetics Corporation | P1/2 | B |
+42 more in the Brain Cancer cohort
Other indications for Vorinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 68 |
| Hodgkins Lymphoma | — | P2 | BB · 68 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vorinostat in Brain Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vorinostat-brain-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →